A double-blind, parallel group, randomised, placebo controlled study of efficacy and safety of Circadin [melatonin] 2 mg in the treatment of insomnia patients with low endogenous melatonin.

Trial Profile

A double-blind, parallel group, randomised, placebo controlled study of efficacy and safety of Circadin [melatonin] 2 mg in the treatment of insomnia patients with low endogenous melatonin.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Melatonin (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors NEURIM Pharmaceuticals
  • Most Recent Events

    • 20 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jan 2009 Planned end date changed from 1 Apr 2008 to 1 Apr 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top